A Phase 2 interventional study of ACP-196 (acalabrutinib) in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.
Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 21st largest by enrollment, is one of 2 that started in 2016, is one of 22 in phase 2, reaches primary completion later than 2 of the 27 other live ones, and was the 7th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Austria, Brazil and 6 more countries
Ages 18–130
Zulfa Omer · Sites in United States
Ages 18+
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Seema Bhat · Sites in United States
Ages 18+
By country, each count listing its studies:
acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 9 · Phase 4 1
First in 2014; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 61 across the 39 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Acerta Pharma BV, one of the names counted as AstraZeneca. Under that name alone:
Acerta Pharma BV is the lead sponsor of 41 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 3 (25%) have results posted.
42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca: 6 open now, 21 under way, 5 of them phase 3. Of 18 finished, 10 (56%) have results posted.
Among the 42 studies in Leukemia, Lymphocytic, Chronic, B-Cell by AstraZeneca, this one is the 18th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2016, is one of 5 in phase 2, reaches primary completion later than 3 of the 20 other live ones, and was the 16th registered.
AstraZeneca’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2005.
9 of the studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT05057494Phase 3AstraZenecaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | 2027-07-15 |
| NCT05971251University of Alabama at BirminghamAddition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | 2026-12-31 |
| NCT06757647Seema BhatAcalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 2026-12-31 |
| NCT05943496OHSU Knight Cancer InstituteTafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among AstraZeneca’s 42 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
A Multicenter, Open-Label, Phase 2 study evaluating the efficacy and safety of Acalabrutinib in subjects with relapsed/refractory CLL (N=60) who are intolerant of ibrutinib therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACP-196 (acalabrutinib) 100 mg to be administered orally (PO) twice a day BID
Drug: ACP-196 (acalabrutinib)
ACP-196 100 mg to be administered orally (PO) twice a day BID.
Also known as: Acalabrutinib
The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib)
The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment.
Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 4 years and 7 months). 1 cycle = 28 days
Progression-Free Survival
The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1.
Time frame: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
Duration of Response
The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1.
Time frame: From the date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Time-to-Next Treatment
The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows: (Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation.
Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)
Overall Survival
The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy
Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years).
| Milestone | Acalabrutinib |
|---|---|
| Started | 60 |
| Completed | 0 |
| Not completed | 60 |
| Withdrew: Death | 13 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Active, not recruiting | 40 |
| Withdrew: Complicating disease | 1 |
The overall response rate (ORR) of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. ORR is defined as the proportion of subjects achieving a best overall response (BOR) of either complete remission (CR), complete remission with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial remission (PR) at or before initiation of subsequent anticancer therapy. ORR will be analyzed per investigator's assessment.
| Percentage of participants | Acalabrutinib |
|---|---|
| The Overall Response Rate (ORR) of ACP-196 (Acalabrutinib) | 70.0 (56.8 to 81.2) |
The progression-free survival of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. PFS is calculated as date of disease progression or death (censoring date for censored subjects) - first dose date + 1.
| Months | Acalabrutinib |
|---|---|
| Progression-Free Survival | NA (33.7 to NA) |
The duration of response of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. DOR is calculated as date of disease progression or death (censoring date for censored subjects) - date of achieving the first CR, CRi, nPR, or PR + 1.
| Months | Acalabrutinib |
|---|---|
| Duration of Response | NA (29.9 to NA) |
The time to next treatment of ACP-196 (acalabrutinib) in subjects with relapsed / refractory CLL who are intolerant of ibrutinib therapy. TTNT is defined as the time from date of first acalabrutinib treatment to date of institution of subsequent anticancer therapy for CLL or death due to any cause, whichever comes first. Subjects who do not have the above specified events prior to the data cutoff date will be censored at the date of last visit. TTNT will be calculated as follows: (Earlier date of institution of subsequent anticancer therapy for CLL or date of death due to any cause) - date of first dose + 1. For censored subjects, date of last visit will replace earlier date of use of subsequent anticancer therapy for CLL or date of death due to any cause in the calculation.
| Months | Acalabrutinib |
|---|---|
| Time-to-Next Treatment | 44.0 (27.4 to NA) |
The overall survival of ACP-319 (acalabrutinib) in subjects with relapsed/refractory CLL who are intolerant of ibrutinib therapy
| Months | Acalabrutinib |
|---|---|
| Overall Survival | NA (NA to NA) |
Collected over From first dose of study drug until 30 days post last dose through study completion. An average of 5 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acalabrutinib | 13/60 (21.7%) | 32/60 (53.3%) | 60/60 (100%) |
| Event | Acalabrutinib |
|---|---|
| PneumoniaInfections and infestations | 7/60 |
| SepsisInfections and infestations | 3/60 |
| SyncopeNervous system disorders | 3/60 |
| Cardiac failure congestiveCardiac disorders | 2/60 |
| Non-cardiac chest painGeneral disorders | 2/60 |
| Bronchopulmonary aspergillosisInfections and infestations | 2/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/60 |
| AnaemiaBlood and lymphatic system disorders | 1/60 |
| Atrial fibrillationCardiac disorders | 1/60 |
| Ventricular fibrillationCardiac disorders | 1/60 |
| Event | Acalabrutinib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 32/60 |
| ContusionInjury, poisoning and procedural complications | 26/60 |
| HeadacheNervous system disorders | 26/60 |
| Upper respiratory tract infectionInfections and infestations | 20/60 |
| DizzinessNervous system disorders | 19/60 |
| CoughRespiratory, thoracic and mediastinal disorders | 19/60 |
| NauseaGastrointestinal disorders | 15/60 |
| FatigueGeneral disorders | 15/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 14/60 |
| PyrexiaGeneral disorders | 12/60 |
| Age, Continuous(Years) | Acalabrutinib |
|---|---|
| Mean | 69.2 ± 9.4 |
| Sex: Female, Male(Participants) | Acalabrutinib |
|---|---|
| Female | 22 |
| Male | 38 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib |
|---|---|
| Hispanic or Latino | 2 |
| Not Hispanic or Latino | 54 |
| Not Reported | 4 |
| Race/Ethnicity, Customized(Participants) | Acalabrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Black or African American | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| White | 56 |
| Other | 1 |
| Not Reported | 2 |
| Region of Enrollment(Participants) | Acalabrutinib |
|---|---|
| United States | 49 |
| Europe | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Mar 2016 to primary completion in Oct 2020, 55 months.
Results were first posted in Feb 2022, 1 year 3 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 55 months is close to that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acalabrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →